Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic Benign Prostatic Hyperplasia (BPH)

• Status: Unknown status
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to compare the efficacy and safety of tamsulosin 0.4mg (Harnal® D. 0.2mg, 2T) with tamsulosin 0.2mg (Harnal® D 0.2mg, 1T) in patients with severe symptomatic benign prostatic hyperplasia as a first line therapy.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Tamsulosin

Criteria

Inclusion Criteria:

• Severe LUTS : IPSS ≥ 20

Exclusion Criteria:

• Post voided residual urine ≥ 150mL

• Patients performing catheterization

• Urinary tract infection patients

• Patients taking 5 alpha reductase inhibitor

• Known hypersensitivity to tamsulosin

• History of postural hypotension or syncope

• Hypertension patients treated with other alpha1-blockers

• Patients newly taking anticholinergic medication within 1 month

• Hepatic insufficiency (AST/ALT ≥ 2 times of normal range)

• Renal insufficiency (s-Cr ≥ 2mg/dL)